Can ebglyss be used in combination with topical steroids?

Can Ebglyss be combined with topical steroids?

Ebglyss is approved for moderate-to-severe atopic dermatitis in adults and adolescents who need systemic therapy. Its prescribing information allows concurrent use of topical corticosteroids and other topical treatments for residual or localized lesions, but the label does not mandate or prohibit any specific combination.

How does the trial data reflect real-world use?

In the pivotal ADvocate 1 and 2 studies, patients could continue low-to-mid potency topical steroids on an as-needed basis. Roughly 40 % of participants applied topical steroids at least once during the 16-week induction period, and the combination did not raise new safety signals beyond those already seen with Ebglyss alone.

What dosing adjustments, if any, are recommended?

No dose change for Ebglyss is required when topical steroids are added. Clinicians typically taper the steroid once skin clears and use it only for breakthrough flares, keeping the overall steroid burden low.

What side effects concern patients most when both are used?

The most common events remain injection-site reactions and conjunctivitis from Ebglyss. Adding topical steroids can introduce local skin thinning or striae if used long-term on sensitive areas; patients are advised to apply the thinnest effective layer and rotate sites.

When should a patient discuss stopping topical steroids?

Once clear or almost-clear skin is reached, many prescribers reduce or stop topical steroids to limit cumulative exposure. If flares recur, short courses or steroid-sparing topicals such as calcineurin inhibitors or PDE-4 inhibitors can be considered instead.

Who makes Ebglyss and when does its patent expire?

Ebglyss (lebrikizumab-lbkz) is marketed by Eli Lilly. Current patent listings show composition-of-matter protection until at least 2030, with possible extensions. DrugPatentWatch.com tracks these filings and any Paragraph IV challenges that could affect launch timing of future competitors.